Effects of dexmedetomidine on immune response in patients undergoing radical and reconstructive surgery for oral cancer

Huang,Lili; Qin,Chuanqi; Wang,Li; Zhang,Tiejun; Li,Jianguo

doi:10.3892/ol.2020.12367

Effects of dexmedetomidine on immune response in patients undergoing radical and reconstructive surgery for oral cancer

Authors:
- Lili Huang
- Chuanqi Qin
- Li Wang
- Tiejun Zhang
- Jianguo Li
View Affiliations

Affiliations: Department of Intensive Care Unit, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China, Department of Anesthesiology, School and Hospital of Stomatology, Wuhan University, Wuhan, Hubei 430079, P.R. China
Published online on: December 10, 2020 https://doi.org/10.3892/ol.2020.12367
Article Number: 106
Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Oral cancer is one of the most common malignancies in the world. The present study aimed to investigate the effects of dexmedetomidine on immune response in patients undergoing radical and reconstructive surgery for oral cancer. Patients were randomly divided into the dexmedetomidine and control groups. Within 15 min before anesthesia induction, dexmedetomidine was infused with a 0.5 µg·kg^‑1 loading dose followed by a maintenance dose of 0.4 µg·kg^‑1·h^‑1 to the end of operation in the dexmedetomidine group, whereas the same volume of saline was administered in the control group. Blood samples were obtained at five time‑points: 30 min Before induction (T₀), 1 h after induction (T₁), end of the operation (T₂) and 24 (T₃) and 48 h (T₄) after the operation. The T lymphocyte subsets (including CD3⁺, CD4⁺ and CD8⁺ cells) and CD4⁺/CD8⁺ ratio, B lymphocytes, dendritic cells and myeloid‑derived suppressor cells (MDSCs) were analyzed by flow cytometry. All immunological indicators, except CD8⁺ cells, significantly decreased between the two groups at T_1‑3 compared with T₀ (P<0.05). The percentages of CD3⁺, CD4⁺, dendritic cells and the CD4⁺/CD8⁺ ratios were significantly higher at T_2‑4 and the percentages of MDSCs were significantly lower at T_2‑4 in the dexmedetomidine group compared with the control group (all P<0.05). These findings suggested that dexmedetomidine can attenuate immunosuppression in patients undergoing radical and reconstructive surgery for oral cancer.

View Figures

View References

1	Kumar M, Nanavati R, Modi TG and Dobariya C: Oral cancer: Etiology and risk factors: A review. J Cancer Res Ther. 12:458–63. 2016. View Article : Google Scholar : PubMed/NCBI
2	Hussein AA, Helder MN, de Visscher JG, Leemans CR, Braakhuis BJ, de Vet HCW and Forouzanfar T: Global incidence of oral and oropharynx cancer in patients younger than 45 years versus older patients: A systematic review. Eur J Cancer. 82:115–127. 2017. View Article : Google Scholar : PubMed/NCBI
3	Hogan BV, Peter MB, Shenoy HG, Horgan K and Hughes TA: Surgery induced immunosuppression. Surgeon. 9:38–43. 2011. View Article : Google Scholar : PubMed/NCBI
4	Kim R: Anesthetic technique and cancer recurrence in oncologic surgery: Unraveling the puzzle. Cancer Metastasis Rev. 36:159–177. 2017. View Article : Google Scholar : PubMed/NCBI
5	Kurosawa S and Kato M: Anesthetics, immune cells, and immune responses. J Anesth. 22:263–277. 2008. View Article : Google Scholar : PubMed/NCBI
6	Zhang T, Fan Y, Liu K and Wang Y: Effects of different general anaesthetic techniques on immune responses in patients undergoing surgery for tongue cancer. Anaesth Intensive Care. 42:220–227. 2014. View Article : Google Scholar : PubMed/NCBI
7	Plein LM and Rittner HL: Opioids and immune system-friend or foe. Br J Pharmacol. 175:2717–2725. 2018. View Article : Google Scholar : PubMed/NCBI
8	Stollings LM, Jia LJ, Tang P, Dou H, Lu B and Xu Y: Immune modulation by volatile anesthetics. Anesthesiology. 125:399–411. 2016. View Article : Google Scholar : PubMed/NCBI
9	Mahmoud M and Mason KP: Dexmedetomidine: Review, update, and future considerations of pediatric perioperative and periprocedural applications and limitations. Br J Anaesth. 115:171–182. 2015. View Article : Google Scholar : PubMed/NCBI
10	Maud AS, Michel MR, Laura NH, Clements RM, Anthony RA and Pieter C: Clinical pharmacokinetics and pharmacodynamics of dexmedetomine. Clin Pharmacokinet. 56:893–913. 2017. View Article : Google Scholar : PubMed/NCBI
11	Yang XH, Bai Q, Lv MM, Fu HG, Dong TL and Zhou Z: Effect of dexmedetomidine on immune function of patients undergoing radical mastectomy. Eur Rev Med Pharmacol Sci. 21:1112–1116. 2017.PubMed/NCBI
12	Wang K and Li C: Effects of dexmedetomidine on inflammatory factors, T lymphocyte subsets and expression of NF-κB in peripheral blood mononuclear cells in patients receiving radical surgery of colon carcinoma. Oncol Lett. 15:7153–7157. 2018.PubMed/NCBI
13	Wang Y, Xu X, Liu H and Ji F: Effects of dexmedetomine on patients undergoing radical gastrectomy. J Surg Res. 194:147–153. 2015. View Article : Google Scholar : PubMed/NCBI
14	Mayhew D, Mendonca V and Murthy BVS: A review of ASA physical status-historical perspectives and modern developments. Anesthesia. 74:373–379. 2019. View Article : Google Scholar
15	Scott NW, McPherson GC, Ramsay CR and Campbell MK: The method of minimization for allocation to clinical trials: A review. Control Clin Trials. 23:662–674. 2002. View Article : Google Scholar : PubMed/NCBI
16	Barr J, Fraser GL, Puntillo K, Ely EW, Gélinas C, Dasta JF, Davidson JE, Devlin JW, Kress JP, Joffe AM, et al: Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the Intensive Care Unit. Crit Care Med. 41:263–306. 2013. View Article : Google Scholar : PubMed/NCBI
17	Chen L, Jondal M and Yakimchuk K: Regulatory effects of dexamethasone on NK and T cell immunity. Inflammopharmacology. 26:1331–1338. 2018. View Article : Google Scholar : PubMed/NCBI
18	Ebert TJ, Hall JE, Barnev JA, Uhrich TD and Colinco MD: The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology. 93:382–394. 2000. View Article : Google Scholar : PubMed/NCBI
19	Xiang H, Hu B, Li Z and Li J: Dexmedetomine controls systemic cytokine levels through the cholinergic anti-inflammatory pathway. Inflammation. 37:1763–1770. 2014. View Article : Google Scholar : PubMed/NCBI
20	Goldfarb Y, Sorski L, Benish M, Levi B, Melamed R and Ben-Eliyahu S: Improving postoperative immune status and resistance to cancer metastasis: A combined perioperative approach of immunostimulation and prevention of excessive surgical stress responses. Ann Surg. 253:798–810. 2011. View Article : Google Scholar : PubMed/NCBI
21	Steinman RM: Decisions about dendritic cells: Past, present, and future. Annu Rev Immunol. 30:1–22. 2012. View Article : Google Scholar : PubMed/NCBI
22	Mildner A and Jung S: Development and function of dendritic cell subsets. Immunity. 40:642–656. 2014. View Article : Google Scholar : PubMed/NCBI
23	Den Brok MH, Nierkens S, Figdor CG, Ruers TJ and Adema GJ: Dendritic cells: Tools and targets for antitumor vaccination. Expert Rev Vaccines. 4:699–710. 2005. View Article : Google Scholar
24	Dai J, El Gazzar M, Li GY, Moorman JP and Yao ZQ: Myeloid-derived suppressor cells: Paradoxical roles in infection and immunity. J Innate Immun. 7:116–126. 2015. View Article : Google Scholar : PubMed/NCBI
25	Tamadaho RSE, Hoerauf A and Layland LE: Immunomodulatory effects of myeloid-derived suppressor cells in diseases: Role in cancer and infections. Immunobiology. 223:432–442. 2018. View Article : Google Scholar : PubMed/NCBI
26	Marvel D and Gabrilovich DI: Myeloid-derived suppressor cells in the tumor microenvironment: Expect the unexpected. J Clin Invest. 125:3356–3364. 2015. View Article : Google Scholar : PubMed/NCBI
27	Yang X, Li Z, Gao C and Liu R: Effect of dexmedetomidine on preventing agitation and delirium after microvascular free flap surgery: A randomized, double-blind, control study. J Oral Maxillofac Surg. 73:1065–1072. 2015. View Article : Google Scholar : PubMed/NCBI
28	Riker RR, Shehabi Y, Bokesch PM, Ceraso D, Wisemandle W, Koura F, Whitten P, Margolis BD, Byrne DW, Ely EW, et al: Dexmedetomidine vs. midazolam for sedation of critically ill patients: A randomized trial. JAMA. 301:489–499. 2009. View Article : Google Scholar : PubMed/NCBI